EX-10.13





 Exhibit 10.13 

Certain identified information marked with [***] has been excluded from this exhibit because it is not 

material and is of the type that the registrant treats as private and confidential. 

Vendor Agreement 
 Between

 Thorne Research, Inc. 
 And

 BioTE Medical, LLC 

December 1, 2020 

  
 1 














 Certain identified information marked with [***] has been excluded from this exhibit because
it 
 is not material and is of the type that the registrant treats as private and confidential. 

 

 VENDOR AGREEMENT 

This Vendor Agreement (“this Agreement”) is made and entered into as of the 1st day of December 2020 (“the Effective Date”), by and
between Thorne Research, Inc., a South Carolina corporation (“Thorne”), having its offices at 620 Omni Industrial Blvd., Summerville, South Carolina 29486, and BioTE Medical, LLC, a Texas limited liability company (“BioTE”),
having its offices at 1875 West Walnut Hill Lane, Suite 100, Irving, Texas 75038, and who are sometimes referred to individually as a “Party” or together as the “Parties.” 

WHEREAS, the Parties entered into that certain Non-Exclusive
Co-Marketing Agreement, dated May 30, 2019, but the Parties now desire to replace that agreement with the terms, conditions, and obligations of this Agreement; and 

WHEREAS, Thorne intends to provide product and AgeBio testing of up to [***] toward the funding of a clinical trial to be sponsored by and conducted by
BioTE and Thorne; and 
 WHEREAS, Thorne remains engaged in the business of research, development, manufacture, distribution, and sale of a line of
nutritional supplement products that promote better health and wellbeing for patients through health-care practitioners who prescribe or recommend Thorne’s nutritional supplement products to their patients; and 

WHEREAS, BioTE remains engaged in the business of recruiting, training, and supporting physicians and other healthcare providers located in the United
States of America or any of its territories to perform BioTE’s proprietary method of hormone balance (“BioTE Medical Hormone Pellet Therapy”) using pelletized therapeutic products derived from natural plant sources designed to
replicate the body’s normal hormonal levels; and 
 WHEREAS, BioTE commits to a long-term strategic partnership with Thorne to grow the
supplements and wellness products offering for BioTE’s 5,500 practitioners in the U.S. BioTE also commits to work with Thorne to provide supplements for BioTE’s currently unserved international practitioners. BioTE has invested
considerable funds and will continue to invest funds creating a market for these Thorne supplements in the clinical, retail, direct to consumer, and online markets in Mexico and South America. 

WHEREAS, BioTE currently sells only to medical practitioners, BioTE is making a considerable investment in adding direct-to-patient and direct-to-consumer supplement sales. All Thorne-BioTE products will be marketed to these large new markets
in Q1 2021. Although BioTE’s growth with Thorne has been strong in the practitioner market, it will only be a fraction of the new direct-to-patient and direct-to-consumer market. Considerable growth can also be predicted on the automatic delivery/subscription service that will be available at the start of the program in Q1
2021. 

  
 2 














 Certain identified information marked with [***] has been excluded from this exhibit because
it 
 is not material and is of the type that the registrant treats as private and confidential. 

 

 WHEREAS, BioTE will continue to use Thorne as a contract manufacturer for the current BioTE-labelled
nutritional supplement products listed in Appendix 1, and as mutually agreed on for future nutritional supplement product development and manufacturing for BioTE-labelled nutritional supplement products and, where appropriate and mutually agreed on,
recommend Thorne’s nutritional supplement product line to those health-care practitioners who prescribe and recommend the BioTE Medical Hormone Pellet Therapy to their patients. 

NOW THEREFORE, the Parties agree on the following terms, conditions, and obligations as set forth herein: 

 

	1.	 Validation Study. The Parties anticipate that certain of BioTE’s certified healthcare providers
will conduct a year-long validation study. The Parties further anticipate that Thorne will provide up to, but not more than, [***] in product and AgeBio Testing toward implementing and conducting the validation study. The Parties agree to provide an
appropriate attribution to Thorne’s participation and assistance in the validation study upon publication of the results of such study. 


  

	2.	 Term. Whereas the initial term of the Non-Exclusive Vendor
Agreement was two (2) years; i.e., the term of that agreement would have expired on May 29, 2021, the initial term of this Agreement will be three (3) years; i.e., the expiration date of this Agreement will be November 30, 2023;
provided, however, that either Party may terminate this Agreement at any time for business convenience by providing a 180-day written notice to the other Party. 



 

	3.	 Drop Ship Agreement. The Parties agree that certain Drop Ship Agreement previously agreed to and
executed by the Parties on May 30, 2019 (Appendix 2) will remain in place, and the Parties agree to continue to comply with its terms, conditions, and obligations, and such Drop Ship Agreement is incorporated by reference herein.
Notwithstanding the foregoing, the Parties agree that if BioTE moves from a drop ship arrangement to an agreement with a third-party logistics provider, the Parties will review and revise the Drop Ship Agreement in place to address such change in
shipping arrangements. 


  

	4.	 Quality Agreement. The Parties agree to the terms, conditions, and obligations of the Quality Agreement
attached as Appendix 3, below, which is executed by the Parties as of the Effective Date of this Agreement and is incorporated by reference herein. 


  

	5.	 Sales Strategies. The Parties agree to continue to use commercially reasonable efforts by Thorne’s
sales representatives to expose, instruct, and recommend the BioTE Medical Hormone Pellet Therapy to their health-care practitioner customers, and by BioTE to expose, instruct, and recommend BioTE-branded and Thorne’s nutritional supplement
product line to BioTE’s health-care practitioner customers. 



  
 3 














 Certain identified information marked with [***] has been excluded from this exhibit because
it 
 is not material and is of the type that the registrant treats as private and confidential. 

 


	6.	 Sales and Marketing Materials. The Parties agree to work together to develop sales and marketing
materials to be used by Thorne and BioTE, respectively, to facilitate the accomplishment of the Sales Strategies set forth in Paragraph 5, above. 


  

	7.	 Training. The Parties agree to make training available to each Party’s respective sales force.



  

	8.	 Commission Structure. Thorne agrees that if any of BioTE’s customers opt to purchase any other non-BioTE branded products, then BioTE will be entitled to receive a [***] commission paid for on a monthly commission cycle for the other products sold, but not including previous Thorne customers who have
purchased product from Thorne in the previous 24 months. 


  

	9.	 Contract Manufacturing. The Parties agree that during the Term of this Agreement, Thorne will continue
to be a manufacturer of the finished nutritional supplement products that bear a BioTE-branded label listed in Appendix 1, subject to the mutually agreed upon production schedule(s) for the manufacture of such products. BioTE further agrees to
continue to purchase such finished products from Thorne as set forth in this Agreement at such time as each lot of finished product is released for sale by Thorne’s Quality Assurance/Quality Control Department, and proof of such release for
sale of finished BioTE-branded product is submitted, with the lot number’s accompanying invoice, to BioTE for approval and payment. BioTE will continue to receive a weekly statement reconciling the previous week’s orders processed by
Thorne, which statement will continue to be emailed to BioTE each week for the previous week’s processed orders. BioTE will continue to receive a [***] discount for payment of a statement within seven (7) days or less from the date of the
statement received and be allowed to pay their invoice by credit card. BioTE will continue to have up to seven (7) days to review the statement for accuracy and make payment by credit card on or before the seventh day to receive the 1-percent early payment discount. If payment is not received by the seventh day after a statement is received by BioTE, then Thorne can seek approval from BioTE to charge BioTE’s credit card on file without a
discount. In the event Thorne experiences an increase greater than ten percent (10%) in raw material or component costs for those items needed in order to manufacture the finished nutritional supplement products for BioTE, Thorne may, upon receipt
of BioTE’s prior written approval, which approval will not be unreasonably withheld, increase the purchase price of the finished nutritional supplement products manufactured for BioTE. 



 

	10.	 Stock. Subject to reasonably accurate and timely rolling
12-month forecasts from BioTE, as well as mutually agreed upon production schedule(s), Thorne continues to commit to remain in stock on those BioTE-branded products manufactured pursuant to Paragraph 9, above.
Thorne agrees to provide written notice to BioTE immediately (i.e., within twenty- four (24) business hours) if an out-of-stock situation occurs, and Thorne agrees
to continue to pay for additional 2-day shipping at no cost to the customer or BioTE. 



  
 4 














 Certain identified information marked with [***] has been excluded from this exhibit because
it 
 is not material and is of the type that the registrant treats as private and confidential. 

 


	11.	 Tracking and Billing. As the Parties deem necessary and by mutual agreement, the Parties agree to
continue to develop processes to track and report the purchases of Thorne’s nutritional supplement products that are consummated as a result of the implementation of the Sales Strategies contemplated in Paragraph 5, above.



  

	12.	 Nutritional Supplement Products. The Parties agree that as of the Effective Date of this Agreement the
nutritional supplement products that BioTE will expose to, instruct on, and recommend to their health-care practitioner customers are those listed in Appendix 1. By mutual agreement, the Parties reserve the right to add additional nutritional
supplement products during the Term of this Agreement. 


  

	13.	 Forecasts. Thorne and BioTE will continue to work closely together, and in good faith, to put in place
rolling 12-month quarterly forecasts for production, which will be updated bimonthly based on historic and future trends. 



 

	14.	 Shipping / Returns. Thorne’s modified shipping rates as agreed on by the Parties in Appendix 2 of
the previous Non-Exclusive Vendor Agreement will continue to apply as the shipping rates during the Term of this Agreement, and former Appendix 2 is incorporated by reference herein as Appendix 2. Returns will
continue to be addressed by the Parties on a case-by-case basis. 


  

	15.	 No Representations or Warranties. Neither Thorne nor BioTE are authorized to make representations or
warranties on behalf of the other with respect to the BioTE Medical Hormone Pellet Therapy or Thorne’s nutritional supplement products, respectively, that are not otherwise contained in the sales and marketing materials contemplated by
Paragraph 6, above, or otherwise authorized by the prior written consent of the Party for whom the representation or warranty might apply. 


  

	16.	 Regulatory Compliance and Oversight. Each Party will be solely responsible for its compliance with the
applicable laws and regulations pertaining to the manufacture, marketing, and distribution of its products and services. 


  

	 	(a)	 Thorne will be responsible for adverse event reporting for the Thorne nutritional supplement products that
BioTE recommends to its affiliated providers. 


  

	 	(b)	 Thorne will be responsible for complying with the regulatory requirements, policies, and procedures associated
with manufacturing, distributing, and marketing its nutritional supplement product line. 


  

	17.	 Product Discontinuance. Either Party may discontinue at any time, with at least one hundred twenty
(120) days’ prior written notice to the other Party, any product. In the event BioTE discontinues a BioTE-branded product, then BioTE will be obligated to purchase, within one hundred eighty (180) days, any inventory of that
discontinued product existing as of the date BioTE provided written notice of discontinuance. 



  
 5 














 Certain identified information marked with [***] has been excluded from this exhibit because
it 
 is not material and is of the type that the registrant treats as private and confidential. 

 


	18.	 Force Majeure. Except for payments due under this Agreement, neither Party will be responsible for any
failure to perform or delay in performance if such failure or delay is caused, directly or indirectly, by events or circumstances beyond such Party’s reasonable control (each a “Force Majeure”), including, but not limited to, acts of
God, war, sabotage, riot, embargoes, compliance with court orders, acts of civil or military authorities, domestic or foreign acts of terrorism, denial of or delays in processing of export license applications, fire, lightening, epidemic, pandemic,
floods or other severe weather conditions, earthquakes, accidents, strikes, fuel crises, interruptions or delays in transportation or communication facilities, or any other event or circumstance, whether similar or dissimilar to those set forth
herein, provided that such Party gives prompt written notice thereof to the other Party and takes reasonable steps to minimize the effect of the event on such Party’s performance. The time for performance will be extended for a period equal to
the duration of the Force Majeure, but in no event longer than sixty (60) days. After such time, the other Party will have the right to immediately terminate this Agreement. 



 

	19.	 Indemnification. Each Party agrees to indemnify the other Party and hold it harmless from all claims,
demands, damages, and liabilities of any kind to the extent any such claim, demand, damage, or liability arises as a result of the implementation of their respective obligations undertaken by the Parties in the performance of this Agreement.



  

	20.	 Intellectual Property; BioTE’s customers. The Parties acknowledge that each Party exclusively owns
the right, title, and interest in its respective intellectual property, and that nothing in this Agreement transfers or inhibits the other Party’s exclusive ownership thereof. Without limiting the generality of the foregoing, the Parties agree
that any proprietary formulations developed by BioTE will remain the sole and exclusive property of BioTE, regardless of whether BioTE utilizes Thorne to manufacture or produce any such products on BioTE’s behalf. Thorne acknowledges that the
customers that it ships to on behalf of BioTE are part of BioTE’s intellectual property. Thorne further acknowledges and agrees that it must obtain BioTE’s written approval prior to marketing any products, services, or items to
BioTE’s customers. As used in this Paragraph 20, the term “marketing” will include, without limitation, electronic messaging, text messaging, telephone calls, in-person meetings, mailings, the
gifting of samples, and any other advertising or soliciting of BioTE’s customers by Thorne. Notwithstanding the foregoing, this prohibition does not include previous Thorne customers who purchased product from Thorne in the twenty-four
(24) month period prior to the effective date of the Parties’ previous Non-Exclusive Vendor Agreement. 


  

	21.	 Confidentiality. The Parties agree that neither Party will disclose or use, without the other
Party’s prior written consent, any non-public, confidential, or proprietary information of the other Party, including, but not limited to, trade secrets, product development information, business
operations information, or customer information, that has been provided to the other Party in furtherance of undertaking their respective obligations. 



  
 6 














 Certain identified information marked with [***] has been excluded from this exhibit because
it 
 is not material and is of the type that the registrant treats as private and confidential. 

 


	22.	 Notices. Any notice required or desired to be given pursuant to this Agreement will be deemed to have
been given when such notice, in writing, is delivered to the other Party at the respective address first written above and addressed to the individual undersigned below. 



 

	23.	 Relationship of the Parties. Nothing contained in this Agreement will be construed as creating a joint
venture, partnership, or agency relationship between the Parties, nor will either Party have the right, power, or authority to create any obligation or duty, express or implied, on behalf of the other Party. 



 

	24.	 Governing Law. The Parties agree that this Agreement will be governed by the laws of the State of
Delaware, without regard to Delaware’s rules relating to conflicts of laws, and the Parties hereby consent to the jurisdiction of the federal and state courts of the State of Delaware relating to any action, suit, or proceeding brought to
compel performance of any obligation undertaken herein by the Parties. 


  

	25.	 Entire Agreement; Amendments. This Agreement and attached Appendices, and the documents incorporated by
reference in this Agreement, constitute the entire agreement between the Parties with respect to the subject matter hereof and supersedes all prior agreements between the Parties with respect to its subject matter. No amendment, change, waiver, or
discharge hereof will be valid unless in writing and signed by the Party against which such amendment, change, waiver, or discharge is sought to be enforced. 



[SIGNATURE PAGE FOLLOWS] 

  
 7 














 Certain identified information marked with [***] has been excluded from this exhibit because
it 
 is not material and is of the type that the registrant treats as private and confidential. 

 

 IN WITNESS WHEREOF, the Parties have executed this Vendor Agreement as of the Effective Date above
written. 
  

	
	FOR THORNE RESEARCH, INC.
	
	/s/ Paul F. Jacobson
	By:   Paul F. Jacobson
	Its:    Chief Executive Officer
	
	FOR BIOTE MEDICAL, LLC
	
	/s/ Terry Weber
	By:   Terry Weber
	Its:    Chief Executive Officer


  
 8 














 Certain identified information marked with [***] has been excluded from this exhibit because
it 
 is not material and is of the type that the registrant treats as private and confidential. 

 

 Appendix 1 

Current BioTE-labelled Nutritional Supplement Products 

Methyl Guard Plus 
 Meriva 500
SF 
 DIM SGS + 
 ADK 5 

ADK 10 
 FloraSport Probiotic

 Iodine 
 Omega w/CoQ10 

Bacillus Coagulans 

  
 9 














 Certain identified information marked with [***] has been excluded from this exhibit because
it 
 is not material and is of the type that the registrant treats as private and confidential. 

 

 Appendix 2 

Shipping Provisions 
 All shipping of BioTE
products will be coordinated through Thone’s Shipping Department, who will be responsible for determining and administering the most cost-effective and timely means of transit. 

Orders will be processed for fulfillment from 8:30 am to 7:00 pm ET (4 pm PT). 

Within the continental U.S., the following shipping terms will apply: 
  

	 	●	 	 Free shipping (delivery within 1 to 3 business days of order) for any order of 1 case or more.



  

	 	●	 	 1-day air will be billed to BioTE at [***] per shipment.



 Shipments to Hawaii will be billed to BioTE at [***], with delivery being 3 business days from
pick-up. 
 The Shipping Department will also coordinate International shipments as required. 

 

	 	●	 	 For Canada — BioTE will be charged [***] per shipment with delivery within 3 business days of order.



  

	 	●	 	 For Puerto Rico, the U.S. Virgin Islands and other Caribbean locations — BioTE will be charged [***] per
shipment with delivery within 3 business days of order. 


 Discounts for Order Processing for BioTE 3PL 

During the term of this agreement, if and when BioTE elects uses their own third party logistics provider (3PL) for order fulfillment, Thorne agrees to a [***]
per bottle discount as Thorne will no longer be required provide order processing (pick-pack-ship) direct to Clinics or Patients, and only ship in bulk quantities to the selected BioTE 3PL. 

  
 10 














 Certain identified information marked with [***] has been excluded from this exhibit because
it 
 is not material and is of the type that the registrant treats as private and confidential. 

 

 Appendix 3 

Quality Agreement 
 This Quality Agreement
(“this Agreement”) is made as of the 1st day of December 2020, by and between: 
 Thorne Research, Inc. (“Thorne”)
having a principal place of business at 620 Omni Industrial Blvd., Summerville, South Carolina 29486, with an FDA Food Facility Registration Number of 11647265648, 

and 
 BioTE Medical, LLC
(“BioTE”) having a principal place of business at 1875 West Walnut Hill Lane, Suite 100, Irving, Texas 75038. 
 WHEREAS,
BioTE has contracted with Thorne to provide manufacturing services in respect of certain Products (as set forth in Exhibit 1 of this Agreement) (the “Products”); and 

WHEREAS, the parties desire to allocate the responsibility for procedures and Specifications, as defined below in Section 1.1 and set out
in Exhibit 1 herein, impacting on the identity, strength, quality, and purity of the Products. 
 NOW THEREFORE, in consideration for the
promises and agreements contained herein, the parties agree as follows: 
  

	1.0	 GENERAL REQUIREMENTS 



 

	1.1	 Specifications 



Both parties acknowledge that Thorne’s and BioTE’s businesses and operations are regulated by the U.S. Food and Drug Administration
(“FDA”) and therefore agree to comply with the requirements of this Agreement and the Specifications. For purposes of clarity, the terms and conditions of this Agreement will apply to the Products set forth in Exhibit 1, as well as any
future products manufactured by Thorne on behalf of BioTE. 
  

	1.2	 Division of Responsibilities 



This Agreement defines the responsibilities of Thorne and BioTE for assuring compliance with current Good Manufacturing Practices (21 CFR Part
111), and quality activities associated with production, packaging, testing, and release of Products (“cGMPs”). 

  
 11 














 Certain identified information marked with [***] has been excluded from this exhibit because
it 
 is not material and is of the type that the registrant treats as private and confidential. 

 


	1.3	 Business Terms 



This Agreement does not define the business terms relating to the commercial supply of Products. To the extent there is conflict or
inconsistency between the provisions of this Agreement and a BioTE purchase order and/or the Non-Exclusive Co-Marketing Agreement between Thorne and BioTE, the terms of
the Purchase Order and/or such Non-Exclusive Co-Marketing Agreement will govern with respect to the terms and conditions relating to the business and commercial supply
requirements for Products. 
  

	1.4	 Attached Exhibits 



Listed below are the following Exhibits that are attached hereto and incorporated into this Agreement: 

Exhibit 1 — Products and Specifications 
  

	2.0	 REGULATORY COMPLIANCE 



 

	2.1	 Product and Facility Compliance 



Thorne will itself manufacture, except for as set forth in Section 15.0, Products in accordance with the requirements of cGMPs. 

Thorne will conduct manufacturing operations in accordance with current cGMP guidelines and accepted industry practices during the term of this
Agreement. These requirements include maintaining a quality assurance system and facility that complies with and satisfies the requirements of 21 CFR Part 111, or an equivalent standard, where applicable, for any electronic records and computer
systems. 
 Thorne and BioTE are responsible for complying with the regulatory requirements that are specifically set forth in this Agreement
or the Division of Responsibilities. 
  

	2.2	 Compliance: Audits 



Thorne may be periodically audited upon reasonable notice by BioTE or an approved BioTE agent for compliance to current cGMPs and BioTE
requirements and to assess the effectiveness of Thorne’s quality system. Thorne will allow BioTE reasonable access to the facility, to appropriate personnel, and to relevant documents, including laboratory testing notebooks. The cost of such
audit will be borne by BioTE. Trade secret documents that relate to formulas and manufacturing processes will need approval from Thorne’s Chief Operating Officer prior to sharing documents with BioTE. Documents will not be transmitted
electronically, but can be viewed as hard copies during compliance audits. 

  
 12 














 Certain identified information marked with [***] has been excluded from this exhibit because
it 
 is not material and is of the type that the registrant treats as private and confidential. 

 


	2.3	 FDA Food Facility Registration 



Thorne is responsible to register its manufacturing facility with the FDA and to maintain the registration documents such that they are readily
available for inspection, as the case may be. 
 Thorne’s current FDA Food Facility Registration Number is 11647265648. 

 

	2.4	 Regulatory Inspections 



Thorne will notify BioTE’s Quality Control of any regulatory inspections and state or federal correspondence (which include, but are not
limited to, FDA Form 483s, FDA Warning Letters, and FDA or state board inspection reports, among others) concerning Product quality within three (3) business days or sooner. Thorne will also provide a copy of any such inspection reports or
copies of any correspondence received from state or federal regulators to BioTE within three (3) business days or sooner per lawyer client privileges. 

BioTE will notify Thorne of any regulatory inspections that BioTE is subject to that implicate Thorne or involve any of Thorne’s products
manufactured under BioTE’s label, and Thorne agrees to be immediately available by telephone to provide any appropriate documentation that BioTE will need to satisfy the inspection. BioTE to provide a copy of inspection reports related to
Thorne manufactured products within three business days of receiving the final report. 
  

	2.5	 Qualifications and Training 



Procedures will be established by Thorne to assure that all personnel are adequately educated and routinely trained according to cGMP regulations and job
functions. 
 Thorne will maintain and record training documents, and will provide evidence of personnel qualification and routine training to BioTE
immediately upon request. 
  

	3.0	 CONTROL DOCUMENTATION AND CHANGE CONTROL 



 

	3.1	 Control Documentation 



Thorne will maintain on site a system of written quality procedures, manufacturing instructions, and facility operations that reflect the
processes set forth in the specifications. In addition, Thorne will, in accordance with cGMPs, maintain a change management system that tracks and controls changes to such documents. 

  
 13 














 Certain identified information marked with [***] has been excluded from this exhibit because
it 
 is not material and is of the type that the registrant treats as private and confidential. 

 


	3.2	 Change Control 



Thorne will provide BioTE with at least thirty (30) days’ prior written notice of any significant changes that have potential effects
on the quality and/or marketing authorization of the products listed within this document. Change requests will confirm that product characteristics will be unaffected and will be supported by technical documentation. Significant changes to product
manufacturing or packaging processes, equipment, production sites, tests, or specifications that would require regulatory approval or notification must be mutually agreed upon in writing by Thorne and BioTE. 

The parties mutually agree to make changes to the Products and Specifications (as listed on Exhibit 1) to comply with cGMPs or any governmental
guidelines. Thorne agrees to implement any changes to the extent such changes are necessary to comply with cGMPs and any governmental guidelines. 
  

	3.3	 Other Changes 



Thorne will provide at least thirty (30) days’ prior written notice to BioTE of any proposed changes relating to the storage or
shipment of Products, as well as any planned changes in any facilities or equipment that may impact the manufacturing of Products. 
  

	4.0	 CERTIFICATE OF ANALYSIS AND CERTIFICATE OF COMPLIANCE 



 

	4.1	 Certificate of Analysis 



Thorne will maintain Certificates of Analysis (“COA”) for each batch of Product delivered, and will make such COAs available to BioTE
upon request. In accordance with 21 CFR § 111.75, BioTE will rely on the information provided in the COA provided that: 
  

	 	(a)	 Thorne qualifies the supplier by establishing the reliability of the supplier’s certificate of analysis
through confirmation of the results of the supplier’s tests or examinations; 


  

	 	(b)	 The COA includes a description of the test or examination method(s) used, label claim specifications, and
actual results of the tests or examinations; 


  

	 	(c)	 Thorne maintains documentation of how Thorne qualified the supplier, and forwards such documentation to BioTE
upon BioTE’s request; 


  

	 	(d)	 Thorne periodically re-confirms the supplier’s COA; and



  

	 	(e)	 Thorne’s quality control personnel reviews and approves the documentation setting forth the basis for
qualification (and re-qualification) of any supplier. 



  
 14 














 Certain identified information marked with [***] has been excluded from this exhibit because
it 
 is not material and is of the type that the registrant treats as private and confidential. 

 

 The COA must specify the Product, specifications, including (if available) label claim,
expiration date, and results for the particular lot, and when applicable will include test method reference and the signature of the person authorized to release the lot. Thorne will provide copies of internal and external test data sheets and
chromatograms for applicable analytical tests on request for investigations or as necessary. 
 Thorne will include with the COA any record
of investigation report prepared in response to an unplanned deviation or out-of-specification test result. 

 

	4.2	 Thorne Information 



Thorne will identify knowledgeable and qualified professionals readily accessible who will provide information and respond to queries, as
follows: 
  

	 	(a)	 Notify BioTE in writing of any regulatory agency communications or contacts related to the Products and provide
a copy of documents requested and left by the authorities within one (1) business day. 


  

	 	(b)	 Notify BioTE in writing of stability trends or non-conformance to
specification within three (3) business days. 


  

	 	(c)	 Provide an investigation report for adverse events within 30 business days of Thorne’s receipt of such
complaints, or immediately upon completion of the investigation report, whichever is sooner. 


  

	 	(d)	 Meet with BioTE, as necessary, to discuss technical matters relating to the manufacture of Products.



  

	 	(e)	 Advise BioTE in writing of major unplanned process deviations or confirmed out-of-specification results within one (1) business day of Thorne’s knowledge of the same. 


  

	 	(f)	 Provide a COA (via electronic mail to BioTE’s QA department) for each finished batch shipment of Product.



  

	5.0	 INVESTIGATIONS OF DEVIATIONS 



 

	5.1	 Deviations 



Thorne will investigate thoroughly any unplanned deviation from approved procedures or out-of-specification test results, or any deviation that results from noncompliance with 21 C.F.R. § 101.9(g)(4)(i), that is, a deviation that results when the nutrient content of the composite is not
formulated to be at least equal to the value for that nutrient declared on the product’s label. Such investigation must adhere to an approved written procedure and be documented. Review and approval of such investigation by Thorne’s
Quality Assurance is required prior to disposition or disposal of the Product, if required and necessary. No Product involved in an investigation may be distributed or released to BioTE until the investigation is completed. 

  
 15 














 Certain identified information marked with [***] has been excluded from this exhibit because
it 
 is not material and is of the type that the registrant treats as private and confidential. 

 


	5.2	 Notification and Report 



Thorne must inform BioTE in writing of any major planned deviation, major unplanned deviation, or confirmed out-of-specification result affecting a Product’s quality after manufacturing or packaging, and submit to BioTE an investigation plan prior to completion of the investigation. Examples of situations that
require an investigation and report include: (i) Confirmed out-of-specification laboratory result; (ii) major process deviation; (iii) failure of
equipment that affects a Product; and (iv) significant yield deviation in or between bulk, packaged Product, and labeling. 
 A report
on root cause of the problem and corrective action/preventative action plan is due within thirty (30) calendar days of the discovery of any major process deviation or confirmed out of specification result. 

 

	6.0	 PRODUCT TESTING 



 

	6.1	 Written Procedures 



Thorne will have and follow written procedures in place for sampling and testing each batch of the Product prior to release. Such procedures
include the following: 
  

	 	(a)	 Examination of a representative sample of units during packaging operations for correct labeling.



  

	 	(b)	 Laboratory test records for conformance to Specifications, including identity, strength, purity, and potency of
selected dietary ingredients. 


  

	 	(c)	 Current and approved validated test methods and acceptance criteria at the end of manufacturing.



  

	 	(d)	 Sampling plans based on commonly accepted statistical criteria. 



Upon request, Thorne will provide BioTE with written procedures for samples and testing the product. Thorne will allow BioTE the opportunity to
request different and/or additional sampling and product testing only for investigation purposes 

  
 16 














 Certain identified information marked with [***] has been excluded from this exhibit because
it 
 is not material and is of the type that the registrant treats as private and confidential. 

 


	6.2	 Approval by a Qualified Professional 



No batch of Product will be released to BioTE prior to approval by a qualified professional. Thorne will appoint a qualified professional who
will ensure that Products meeting BioTE’s Specifications are released to BioTE. 
  

	7.0	 OBSOLETE, WASTE, AND REJECTED MATERIALS DISPOSITION 



 

	7.1	 Destruction Procedures 



Thorne will certify destruction of any excess, expired, obsolete, or rejected Products or raw materials. Thorne will provide a Certificate of
Destruction attesting that such Products or materials were destroyed at BioTE’s request (“COD”). 
  

	7.2	 Environmental Laws 



Thorne will comply with federal, state, and local applicable environmental and safety laws and regulations pertaining to handling of any waste
arising from the manufacture of Products. 
  

	8.0	 PRODUCT COMPLAINT MANAGEMENT 



Thorne will comply with all review and investigation process requirements as set forth in the sections below and in 21 CFR 111. 

 

	8.1	 Product Complaints 



Thorne or BioTE may be notified of complaints received by customers or consumers of the Product. For purposes of this Agreement, “Routine
Complaints” include any complaint that is not life threatening and includes, without limitation, short product count, incorrect address, and delayed shipments. If and when Thorne or BioTE receives a Routine Complaint, the receiver of such a
Routine Complaint must notify the other party within 72 hours, unless such complaint is an Urgent Complaint as defined below. These include complaints received either verbally or in a written format for both Urgent Complaints and Routine Complaints.

 For purposes of this Agreement, “Urgent Complaints” include any complaint that alleges an adverse event; adulteration,
contamination, tampering, misbranding, mislabeling, lack of stability, or that may reasonably be interpreted as having significant safety or regulatory consequences. With respect to Urgent Complaints, Thorne will notify BioTE of receipt of an Urgent
Complaint immediately, and not less than 24 hours after receipt. Further, Thorne will respond to BioTE inquiries in writing immediately upon BioTE’s receipt of an Urgent Complaint, and not less than 24 hours after receipt. 

  
 17 














 Certain identified information marked with [***] has been excluded from this exhibit because
it 
 is not material and is of the type that the registrant treats as private and confidential. 

 


	8.2	 Procedures for Complaints 



The procedures for handling Product complaints must address recording, managing, and investigating complaints, and the party responsible for
recording, reporting, and investigating Product complaints will forward such Product complaints to the other party. 
 Thorne will comply
with all reasonable requests made by BioTE in connection with a Product complaint, the procedures for managing Product complaints, and the investigation thereof of any Product. 

 

	8.3	 Maintaining Records 



A written record of each Product complaint will be received and maintained in accordance with cGMPs, FDA guidelines, and Thorne’s policy
for handling Product complaints. A reasonable attempt should be made to obtain and document the following information on each Product complaint record: 
  

	 	(a)	 Complainant’s name and address, unless the complainant wishes to remain anonymous. 



 

	 	(b)	 Name, strength and dosage form of the Product. 



 

	 	(c)	 Lot number and expiration date. 



 

	 	(d)	 Date complaint received and Product returned. 



 

	 	(e)	 Nature of the complaint. 



 

	 	(f)	 Complaint tracking (identification) number. 



 

	8.4	 Storage of Product Returned 



BioTE samples that contain Product (“BioTE Samples”) will be provided by BioTE to Thorne for purposes of complaint investigations, if
available. 
 Thorne will document receipt of BioTE Sample(s) in the complaint record and will maintain BioTE Samples in a secure location.

  

	8.5	 Investigation 



All Routine and Urgent Complaints received by either BioTE or Thorne regarding any of the Products require an investigation. For Routine and
Urgent Complaints, the investigation plan, outline, or list of action steps must be submitted to BioTE. The investigations may be wholly or partially executed by Thorne but must minimally include provisions for: 

  
 18 














 Certain identified information marked with [***] has been excluded from this exhibit because
it 
 is not material and is of the type that the registrant treats as private and confidential. 

 


	 	(a)	 Manufacturing record review. 



 

	 	(b)	 In-Process and Finished Product test results review.



  

	 	(c)	 Shipping and distribution controls review. 



 

	 	(d)	 Packaging record review. 



 

	 	(e)	 Review of complaint and associated files for detection of trends. 



 

	 	(f)	 Review of impact on other Product or additional lots of the same Product. 



 

	 	(g)	 Testing of returned or reserve Product as necessary. 



Investigations on Urgent Complaints will be initiated immediately with a target completion date of seven (7) calendar days. An
investigation report must be issued inclusive of results of all testing performed, data reviews, and trend discoveries, with a conclusion and corrective action/preventative action plan recommendations, as required, at the close of an investigation.
A copy of the final report must be kept on file by Thorne as part of the complaint record. Final investigation reports must be forwarded to BioTE within three (3) business days of completion. 

Product testing on returned or retained samples in the custody of Thorne is at the discretion of Thorne. BioTE may request that Thorne perform
Product testing; however, Thorne will follow its own written procedures for testing returned or retained samples. Any returned or retained samples sent to Thorne not consumed by required testing will be returned to BioTE. 

 

	9.0	 RECALL 



Thorne will have sole responsibility for initiating and managing any recall of BioTE’s Products manufactured or procured by Thorne. BioTE will be
informed prior to the initiation of a recall to the extent that such recall arises out of a breach of its obligations hereunder. 
 There will be timely
exchange of information between Thorne and BioTE about any potential recall, as follows: 
  

	 	(a)	 Thorne will immediately inform BioTE in writing of any circumstances that have come to its attention that may
make a recall necessary. 


  

	 	(b)	 In the event a Regulatory Authority issues or requests a recall, Thorne or BioTE will, within 24 hours, notify
the other party. 



  
 19 














 Certain identified information marked with [***] has been excluded from this exhibit because
it 
 is not material and is of the type that the registrant treats as private and confidential. 

 


	 	(c)	 Within 48 hours of learning that a recall may be necessary, Thorne and BioTE will discuss details of the recall
strategy. 


 BioTE will require a COD should Product be returned to Thorne as the result of a recall. 

Thorne will pay BioTE all reasonable, out-of-pocket, costs, expenses, and
attorneys’ fees borne by BioTE in connection with any recall of Thorne’s products manufactured under BioTE’s label, or in connection with any recall of product whose manufacturing process was outsourced by Thorne but bearing
BioTE’s label. 
  

	10.0	 RECORDS AND RETAINED SAMPLES RETENTION 



Thorne will hold, in a secure manner, original records and representative samples from the manufacture and control of each lot of Product. Product samples
must be stored under controlled and labeled conditions. All production history documentation will be available to BioTE for inspection while onsite. Electronic records will satisfy the requirements of 21 CFR Part 111 or an equivalent standard, where
applicable. 
  

	10.1	 Retained Samples 



Retained samples to be kept per Thorne’s internal procedure and will be provided to BioTE upon BioTE’s request. 

 

	10.2	 Records 



Thorne to follow internal document retention schedule per policy document POL-00001. 

 

	11.0	 REPROCESSING/ REWORKING 



The parties will mutually agree in advance of plans to rework or reprocess Product unless an already agreed on procedure exists and there are no trends, or as
permitted by the terms set forth in this Section. No change will be made to a validated process without the prior written authorization of BioTE. Thorne may not reprocess Product, unless reprocessing to correct defects of the type that from time to
time arise during a packaging run (e.g., jams which damage secondary packaging) due to machine capabilities. Such routine reprocessing must be documented in the packaging record. 

Thorne will have written procedures that describe the system for reworking or reprocessing Product. The system must provide for trending and include
corrective and preventive action. Product recovery will be in keeping with the agreed upon procedure and documented. For Product to be considered releasable, all predetermined Specifications and other quality criteria must be met. 

  
 20 














 Certain identified information marked with [***] has been excluded from this exhibit because
it 
 is not material and is of the type that the registrant treats as private and confidential. 

 


	12.0	 SELF-INSPECTION 



Thorne will maintain a written program of self-inspection by technical personnel for all cGMP areas, as follows: 

 

	 	(a)	 Inspections will be conducted at least annually in keeping with a schedule. Thorne will provide documentation
of such inspections to BioTE upon BioTE’s written request. 


  

	 	(b)	 The persons performing the inspection should be knowledgeable in their respective fields and familiar with
cGMP. 


  

	 	(c)	 A report must be made of the observations. 



 

	 	(d)	 Management must evaluate the observations and corrective action. 



 

	 	(e)	 If applicable, an agreed upon corrective action must be initiated and tracked. 



 

	 	(f)	 A record of the observations and corrective actions will be maintained by Thorne, a copy of which will be
forwarded to BioTE upon request. 


  

	13.0	 STABILITY TESTING AND BEST-USED-BY DATING 



Thorne and BioTE will mutually agree on procedures for determining Best-Use-By
Dating for purchased BioTE products. Thorne will provide BioTE with a written explanation of the data to be used for determining Best-Use-By dates for each item. For all
private-label products where full stability testing has been performed on the finished product, Thorne will provide BioTE with a copy of the final summary report upon request. BioTE may contract with Thorne additional stability testing of finished
Products at BioTE’s expense. That stability testing program will be in writing and include the following elements: 
  

	 	(a)	 Product specific stability protocols that detail sample size, analytical/test methods including known and
unknown impurity profiles and limits, (if applicable), test intervals, storage condition(s), packaging components/configurations and reason for the study 


  

	 	(b)	 Stability-indicating test methods 



 

	 	(c)	 Criteria for batch selection for the program 



 

	 	(d)	 Secure, alarmed, and qualified storage 



 

	 	(e)	 Manual and/or electronic data collection 



 

	 	(f)	 Statistical analysis capability 



  
 21 














 Certain identified information marked with [***] has been excluded from this exhibit because
it 
 is not material and is of the type that the registrant treats as private and confidential. 

 


	 	(g)	 Out-of-specification
investigation and notification mechanism 


  

	 	(h)	 Data summarization and distribution 



Thorne will follow its SOP-00212 “Stability Testing Program.” 

 

	14.0	 STORAGE AND SHIPPING CONDITIONS 



Thorne will store manufactured Products in defined areas under appropriate conditions of temperature, humidity, and light and in accordance with
specifications such that quality is not affected. In addition, Thorne will have written procedures that describe storage, handling and distribution of the Product and minimally address: 

 

	 	(a)	 Periodic verification of actual storage conditions at Thorne’s facility. 



 

	 	(b)	 Storage of semi-finished or finished Product under controlled labeled conditions. 



 

	 	(c)	 Handling of Product that has been subjected to improper storage conditions. 



 

	 	(d)	 Selection and preparation of Product for shipment. 



 

	 	(e)	 Monitoring to ensure shipping conditions have been maintained where requirements exist. 



 

	15.0	 SUBCONTRACTING 



In the event that a Purchase Order authorizes Thorne the right to subcontract Product manufactured, tested, or processed, such contractor must meet cGMP
standards and BioTE’s regulatory requirements. Thorne must ensure that the subcontractor’s personnel are adequately educated and routinely trained according to cGMP regulations and job functions, in accordance with Section 2.6 above.
Thorne must notify BioTE which aspects of manufacturing will be subcontracted and what manufacturing facilities will be used when initial product manufacturing quotes are provided. BioTE agrees this information will be kept confidential and will
only be used for meeting cGMP compliance obligations. Thorne will provide results of audits of subcontracted manufacturing facilities to BioTE on request. 
  

	16.0	 AMENDMENTS 



This Agreement may only be modified by a writing signed by duly authorized representatives of Thorne and BioTE. The failure of either party to insist on
strict performance of any provision of this Agreement, or to exercise any right or remedy, will not be deemed a waiver of such performance, right or remedy, of that or any other provision of this Agreement. 

  
 22 














 Certain identified information marked with [***] has been excluded from this exhibit because
it 
 is not material and is of the type that the registrant treats as private and confidential. 

 


	17.0	 ADDITIONAL TERMS AND CONDITIONS 



If this paragraph is initialed by Thorne and BioTE, then this Agreement is supplemented by the additional terms and conditions contained in the attached
Exhibit 1 (    ), ( ). 
  

	18.0	 FACSIMILIE SIGNATURE 



The Parties agree that a facsimile signature will be deemed an original. 

IN WITNESS WHEREOF, the parties have duly executed this Quality Agreement as of the date first written above and is effective until termination of the
Vendor Agreement between Thorne and BioTE. 
  

	
	FOR BIOTE MEDICAL, LLC
	
	/s/ Terry Weber
	Name: Terry Weber
	Title: Chief Executive Officer

  

	
	FOR THORNE RESEARCH, INC.
	
	/s/ Paul F. Jacobson
	Name: Paul F. Jacobson
	Title: Chief Executive Officer


  
 23 














 Certain identified information marked with [***] has been excluded from this exhibit because
it 
 is not material and is of the type that the registrant treats as private and confidential. 

 

 Appendix 4 

Products and Specifications to be included on Certificate of Analysis 
  

													
	 Product
	  	 Description
	  	 Label Claim
	  	 Exp
Date
	  	 Test
Results
	  	 Test
Method
Reference
	  	 Signature
and Date

	ADK5	  	Capsule/Off-White	  	 Vitamin A (as Retinyl Palmitate) 1.5mg
  

Vitamin D (as D3) 5,000 IU
  

125mcg
  

Vitamin K (as MK04 and MK07)
  

500mcg
	  	Per exp date printed on bottle	  	TBD	  	HPLC	  	Released for use by:
							
	ADK10	  	Capsule/Off- White	  	 Vitamin A (as Retinyl Palmitate) 1.5mg
  

Vitamin D (as Vitamin D3) 10,000 IU
  

250mcg
  

Vitamin K (as MK-4 and MK-7)

 
 500mcg
	  	Per exp date printed on bottle	  	TBD	  	HPLC	  	Released for use by:


  
 24 














 Certain identified information marked with [***] has been excluded from this exhibit because
it 
 is not material and is of the type that the registrant treats as private and confidential. 

 


													
	Iodine Plus	  	Capsule/Off-White	  	 Iodine (as Potassium Iodide)
  

12.5mg
  

Zinc (as Zinc Amino Acid Chelate)
  

10mg
  

Selenium (as L-Selenomethionine)
  

200mcg
	  	TBD	  	TBD	  	HPLC	  	Released for use by:
							
	DIM	  	Capsule/Light Brown	  	 Diindolylmethane (as Crystalline DIM
  

150mg
  

POM Pomegranate extract (whole fruit) (Punica granatum)
  

100mg
  

Sulforaphane Glucosinolate (from broccoli extract (seed) (Brassica oleracea italica))

 
 25mg
	  	24 months from date of production	  	TBD	  	HPLC	  	Released for use by:


  
 25 














 Certain identified information marked with [***] has been excluded from this exhibit because
it 
 is not material and is of the type that the registrant treats as private and confidential. 

 


													
	Omega 3+ CoQ10	  	Gelcap/Orange	  	 EPA (Eicosapentaenoic Acid) (from Fish Oil)
  

450mg
  

DHA (Docosahexaenoic Acid) (from Fish Oil)
  

180mg
  

Coenzyme Q10
  

30mg
	  	Per exp date printed on bottle	  	TBD	  	HPLC	  	Released for use by:
							
	Methyl Factors Plus	  	Capsule/Light Orang	  	 Riboflavin (as Riboflavin 5’- Phosphate Sodium)
  

90mg
  

Vitamin 6 (as Pyridoxal 5’-Phosphate)
  

45mg
  

Vitamin B12 (as Methylcobalamin)
  

3mg
  

Betain Anhydrous (Trimethylglycine)
  

1.8 g
	  	Per exp date printed on bottle	  	TBD	  	HPLC	  	Released for use by:
							
	Curcumin SF	  	Capsule/Orange	  	 Curcumin Phytosome (Curcuma longa extract (root)/Phospholipid complex from Sunflower)

 
 1g
	  	Per exp date printed on bottle	  	TBD	  	HPLC	  	Released for use by:


  
 26 














 Certain identified information marked with [***] has been excluded from this exhibit because
it 
 is not material and is of the type that the registrant treats as private and confidential. 

 


													
	Multi Strain Probiotic 208	  	Capsule/White	  	 HOWARU* Restore II Blend
  

20 Billion CFUs
  

•  Bifidobacterium lactis (Bi-07) 5 Billion CFUs

 
 •  Lactobacillus acidphilus
(NCFM) 5 Billion CFUs
  

•  Bifidobacterium lactis (bi-04) 5 Billion CFUs

 
 •  Lactobacillus paracasei (Lpc-37) 5 Billiob CFUs
	  	Per exp date printed on carton	  	TBD	  	HPLC	  	Released for use by:
							
	Bacillus Coagulans Probiotic	  	Capsule/White	  	 Bacillus Coagulans
  

133mg
  

2 Billion CFUs
	  	TBD	  	TBD	  	HPLC	  	Released for use by:


  
 27